Altimmune
ALT
102 hedge funds and large institutions have $296M invested in Altimmune in 2021 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 39 increasing their positions, 29 reducing their positions, and 34 closing their positions.
64% more call options, than puts
Call options by funds: $8.43M | Put options by funds: $5.15M
34% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 29
0.95% less ownership
Funds ownership: 82.66% → 81.71% (-0.95%)
14% less funds holding
Funds holding: 118 → 102 (-16)
21% less capital invested
Capital invested by funds: $375M → $296M (-$79.1M)
44% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 34
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
+$15.8M |
| 2 |
Citigroup
New York
|
+$10.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$9.54M |
| 4 |
Barclays
London,
United Kingdom
|
+$8.63M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$6.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$43M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$16M |
| 3 |
BSA
Braun Stacey Associates
New York
|
-$8.05M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$7.92M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$5.42M |
ALT Hedge Fund Activity: Q4 2021 in Review
102 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q4 2021, worth a combined $296M — down 21% from $375M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of ALT and 19 opened new positions — a net loss of 15 holders — while 29 trimmed existing stakes and 39 added.
The largest buyer was Nuveen, adding an estimated $15.8M. The largest seller was VR Adviser, exiting entirely with an estimated $43M sold.
- 102 institutional investors held Altimmune (ALT) as of Q4 2021, down from 118 in Q3 2021.
- Funds reported $296M of Altimmune stock for Q4 2021, down 21% quarter-over-quarter.
- 19 funds opened new Altimmune positions in Q4 2021 and 34 closed out, a net change of -15 holders.
- The largest Altimmune buyer in Q4 2021 was Nuveen, an estimated $15.8M added.
- The largest Altimmune seller in Q4 2021 was VR Adviser, an estimated $43M sold.
Based on aggregated 13F filings for Q4 2021.